- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06736379
Entrega intratumoral de partículas de replicon viral (saRNA) que expressam IL-12 em câncer de cabeça e pescoço
Estudo de injeções intratumorais de VLPONC-01 em câncer de cabeça e pescoço
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are:
The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)
The tumor response to IT injections of VLPONC-01
The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment
Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.
Visão geral do estudo
Status
Condições
- Câncer de Cabeça e Pescoço
- Carcinoma Espinocelular de Cabeça e Pescoço
- Tumores Sólidos
- Câncer de Células Escamosas de Cabeça e Pescoço
- Cabeça Pescoço Câncer
- Carcinoma da Cavidade Oral
- HNSCC
- Cavidade Bucal
- Carcinoma de Células Escamosas, Cabeça e Pescoço
- Câncer de Cabeça e Pescoço - Células Escamosas
- Carcinoma Espinocelular de Cabeça e Pescoço
- SCCHN
- CEC - Carcinoma de Células Escamosas
Descrição detalhada
The study is an Open label, Phase I study to determine the safety of IT injected VLPONC-01 as a therapeutic agent in subjects with non-resectable and resectable Head and Neck Cancer Squamous Cell Carcinomas (HCSCC), and secondarily to assess pathologic response and radiological response (assessed by RECIST 1.1 criteria) in the primary tumor and regional lymph nodes. Researchers also will explore tumor microenvironment changes in cytokine levels and cellular responses.
There will be three distinct cohorts enrolling sequentially:
Cohort A: Researchers will enroll unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery who will receive four doses of VLPONC-01.
Cohort C: Researchers will enroll HCSCC patients scheduled for tumor resection surgery who will receive four doses of VLPONC-1 and two doses of neoadjuvant pembrolizumab or only two doses of neoadjuvant pembrolizumab prior to tumor resection surgery.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Clinical Research Coordinator
- Número de telefone: 650-725-9333
- E-mail: tpark22@stanford.edu
Locais de estudo
-
-
California
-
Stanford, California, Estados Unidos, 34305
- Recrutamento
- Stanford University
-
Contato:
- Clinical Research Coordinator
- Número de telefone: 650-725-9333
- E-mail: tpark22@stanford.edu
-
Investigador principal:
- Fred M Baik, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Cohort A - Unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery. With one the following prior treatments:
Subjects must have received a platinum containing chemotherapy regimen, 5-Fluorouracil chemotherapy, taxane based chemotherapy, cetuximab or gemcitabine for treatment of primary tumor in locally advanced, or metastatic settings.
Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy.
Subjects must have progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status).
Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).
Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, therefore these subjects must have been previously treated with an applicable tyrosine kinase inhibitor.
OR Cohort C - Patients with at least 1 measurable resectable lesion clinical stage I-IVb (cT1-4, N0-3) (AJCC, 8th Edition) (Amin, 2017), Histologically or cytologically confirmed HNSCC. Scheduled to undergo tumor surgical resection of the primary tumor.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and adequate bone marrow and organ function.
-
Primary tumors should be amenable to intratumoral (IT) injection >1 cm diameter. This will be determined by the Protocol Director, or the surgeon involved.
-
Subjects with either a local recurrence or a new primary tumor will be allowed.
-
Age ≥ 18 years.
-
Have acceptable organ and marrow function defined as follows:
Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 8.0 g/dL (Note: use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable) Total bilirubin ≤2x institutional upper limit of normal (ULN) AST(SGOT) or ALT(SGPT) ≤ 3.0x institutional ULN
-
Ability to understand and the willingness to provide written informed consent.
-
Life expectancy > 12 weeks (about 3 months).
-
Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria:
- Tumors which are not feasible for injections include high risk lesions that are near vital organs or important neurovascular structures, as determined by the Protocol Director or involved surgeon.
- Women of childbearing potential must have a negative serum β-hCG pregnancy test within 7 days prior to the administration of the first study treatment and/or urine pregnancy 48 hours prior to the administration of the first study treatment. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use two methods of effective contraception, one of them being a barrier method, or to abstain from sexual activity during the study and for at least 6 months after last dose of study drugs.
- Patients expected to receive other anti-cancer medication such as, chemotherapy, immunotherapy, biologic therapy, targeted therapy, monoclonal antibodies, hormonal therapy (other than leuprolide or other GnRH agonists) prior to surgery and where all acute toxicity of prior treatments have not resolved.
- Participation in another clinical study with an investigational product during the last 30 days.
- Uncontrolled intercurrent illness including, that do not respond to active medical intervention.
- Current or prior use of immunosuppressive medication within 28 days before the first dose of injection, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid.
- If applicable: Women who are breastfeeding.
- History of allogenic organ transplant that requires use of immunosuppressives.
- Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
- Any condition that, in the investigator's opinion, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
- Uncontrolled intercurrent illness including those that do not respond to active medical intervention.
- Any contraindication to the use of known history of hypersensitivity to any immune therapy's drugs.
- Subjects must not have received any live vaccine within 28 days prior to the first dose of study treatment.
- Active autoimmune disease that requires systemic therapy, in the Investigator's opinion, may increase the risk of study participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort A (1 x 10^9 viral particles per injection)
Recurrent or Metastatic Head and Neck Cancer not scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly, with an additional follow-up safety visit 30 and 90 days post the final injection. |
Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01
Outros nomes:
|
|
Experimental: Cohort C - Group 1 (1 x 10^9 viral particles per injection plus Pembrolizumab)
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01
Outros nomes:
200mg twice 3 weeks apart IV
Outros nomes:
|
|
Experimental: Cohort C - Group 2 (3 x 10^8 viral particles per injection plus Pembrolizumab)
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
200mg twice 3 weeks apart IV
Outros nomes:
Weekly IT injections of 3 x 10^8 viral particles of VLPONC-01
Outros nomes:
|
|
Experimental: Cohort C - Pembrolizumab only
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
200mg twice 3 weeks apart IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety and tolerability
Prazo: First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
To assess the safety and tolerability of VLPONC-01. Safety will be based on the occurrence of any grade 3 or higher drug-related adverse events from the VLPONC-01 injections for non-surgery patients and any grade 3 or higher drug-related adverse events that result in a delay to tumor resection surgery. |
First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Levels of circulating IL-12
Prazo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
To assess the circulating blood levels of IL-12 after VLPONC-01 treatment compared to baseline to determine the occurrence and safety profile of potential systemic inflammatory responses. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
|
VLPONC-01 levels in tumor tissue
Prazo: First injection to tumor resection surgery
|
To detect levels of VLPONC-01 RNA in surgically resected tissue. |
First injection to tumor resection surgery
|
|
Radiological Tumor Response
Prazo: First injection to tumor resection surgery (up to 3 months)
|
To assess the primary tumor response by RECIST. |
First injection to tumor resection surgery (up to 3 months)
|
|
Pathological Tumor Response
Prazo: First injection to tumor resection surgery (up to 3 months)
|
To assess the primary tumor response by pathological analysis. |
First injection to tumor resection surgery (up to 3 months)
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Circulating levels of cytokines, chemokines, and immune markers
Prazo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess the circulating levels cytokines, chemokines, and immune markers using a proteomics assay. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
ICH Changes in Tumor microenvironment
Prazo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess levels of CD8+ T-cells, macrophages, and other immune cell populations in surgically resected tissue compared to biopsy tissue using immunohistochemistry. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
Changes in ctDNA related to Neoadjuvant treatment
Prazo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess changes in ctDNA MRD treatment-related molecular response (Cohort C). |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
Changes in cellular populations
Prazo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess the changes in cellular populations in circulating blood using flow cytometry. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Fred M Baik, MD, Stanford University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Keytruda
- pembrolizumabe
- Intratumoral
- anti-PD-1
- Injeção de TI
- IL-12
- macrófago
- ressecção de tumor
- saRNA
- Interleucina 12
- VLP
- Partícula semelhante a vírus
- PRV
- Partícula de Replicon Viral
- Encapsulado em VRP
- cirurgia de ressecção de tumor
- RNA autoamplificador
- Múltiplas inoculações diretamente no tumor
- partículas virais por injeção
- partículas virais
Termos MeSH relevantes adicionais
- Doenças bucais
- Doenças estomatognáticas
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Carcinoma
- Neoplasias de Células Escamosas
- Carcinoma Espinocelular de Cabeça e Pescoço
- Carcinoma de Células Escamosas
- Neoplasias de Cabeça e Pescoço
- Neoplasias Bucais
- Pembrolizumab
Outros números de identificação do estudo
- VLPONC-01
- SYNERNA-01 (Outro identificador: VLP Therapeutics, Inc.)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .